News|Articles|November 18, 2026

5 Blood Cancer Studies to Watch at ASH 2026

Fact checked by: CURE staff
Listen
0:00 / 0:00

Key Takeaways

  • Zanubrutinib plus rituximab reduced progression/death risk by 43% versus bendamustine-rituximab in transplant-ineligible untreated MCL, supporting a potential first BTK-based chemo-free frontline regimen.
  • Epcoritamab plus lenalidomide improved PFS versus R-GemOx in R/R DLBCL lacking CAR-T options, with a 56%–60% reduction in progression/death and expected safety.
SHOW MORE

Chemotherapy-free regimens for lymphoma and new drug combinations for myeloma are among the ASH 2026 studies patients should watch.

The American Society of Hematology (ASH) 2026 Annual Meeting runs Dec. 12-15 in New Orleans and online. It is one of the biggest meetings of the year for blood cancer research. Regular abstracts were posted online Nov. 4, and late-breaking abstracts will be posted Dec. 7.

ASH selected a small group of studies for its official press program. Here are five of them, in lymphoma and myeloma, whose drug makers have already shared early results, and why they matter for patients.

A Few Terms That Will Help

Most of these trials measured progression-free survival, or how long people lived without their cancer growing. When a study says a treatment lowered the risk of progression or death by a certain percentage, it is being compared with a standard treatment. "Relapsed" means the cancer came back after treatment, and "refractory" means it stopped responding. A bispecific antibody is a drug that grabs both a cancer cell and an immune cell called a T cell, bringing them together so the T cell can attack.

1. MANGROVE: A Chemotherapy-Free First Treatment for Mantle Cell Lymphoma

Cancer type: Previously untreated mantle cell lymphoma

Abstract: 6

Mantle cell lymphoma is a rare and usually aggressive type of B-cell non-Hodgkin lymphoma that mainly affects older adults. Chemotherapy combined with immunotherapy has long been a standard first treatment.

The phase 3 MANGROVE trial enrolled 510 adults with untreated mantle cell lymphoma who were not eligible for a stem cell transplant. It compared Brukinsa (zanubrutinib), a daily pill known as a BTK inhibitor, plus the immunotherapy rituximab with bendamustine chemotherapy plus rituximab. Brukinsa plus rituximab lowered the risk of progression or death by 43%.

In early November, the FDA accepted BeOne Medicines' application for this combination and granted it priority review. If approved, it would be the first chemotherapy-free regimen built on a BTK inhibitor for this group of patients.

2. EPCORE DLBCL-4: Epkinly Plus Revlimid for Relapsed Large B-Cell Lymphoma

Cancer type: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Abstract: 919

Epkinly (epcoritamab) is a bispecific antibody given as an injection under the skin for a set length of time. EPCORE DLBCL-4 tested it with Revlimid (lenalidomide), a pill, against R-GemOx, a standard combination of rituximab, gemcitabine and oxaliplatin. Patients had received at least one earlier treatment and either could not have, or had already had, a stem cell transplant, and could not receive CAR-T cell therapy.

According to topline results announced by Genmab and AbbVie in June, Epkinly plus Revlimid lowered the risk of progression or death by 60% or 56%, depending on how the data were analyzed. Side effects were consistent with what was already known for each drug. ASH will be the first full look at the data. Read CURE's earlier coverage.

3. LOTIS-5: Zynlonta Plus Rituximab, With Benefits and Trade-Offs

Cancer type: Relapsed or refractory DLBCL

Abstract: 920

Zynlonta (loncastuximab tesirine-lpyl) is an antibody-drug conjugate, a drug that delivers a toxic payload to cancer cells that carry a protein called CD19. LOTIS-5 compared Zynlonta plus rituximab with R-GemOx and serves as the confirmatory trial for Zynlonta's existing accelerated approval.

In topline results released by ADC Therapeutics in June, median progression-free survival was 6.1 months with Zynlonta plus rituximab, compared with 4.7 months with R-GemOx. More patients had no remaining signs of cancer (39.5% vs 26.7%), and among those patients, 48.5% vs 16.7% were still free of cancer at 24 months.

The study also showed important trade-offs. Serious side effects occurred in 49% of patients in the Zynlonta group, compared with 34.5% in the R-GemOx group. Side effects led to death in 13.2% vs 4.6% of patients, and most of those deaths in the Zynlonta group were in people 75 or older. Full results at ASH should help patients and doctors weigh who is most likely to benefit.

4. EXCALIBER-RRMM: A Zenbexus Combination at First or Second Relapse of Myeloma

Cancer type: Relapsed or refractory multiple myeloma

Abstract: 114

Zenbexus (iberdomide) is a pill in a newer drug class called CELMoDs. In August, the FDA granted it accelerated approval with Darzalex Faspro (daratumumab and hyaluronidase-fihj) and the steroid dexamethasone, based on how many patients reached a very deep response in the EXCALIBER-RRMM trial. CURE covered that approval.

The trial included people whose myeloma had come back after one or two earlier treatments. In October, Bristol Myers Squibb reported that median progression-free survival was 42 months with the Zenbexus combination, compared with 20 months with Darzalex Faspro, Velcade (bortezomib) and dexamethasone, a 51% lower risk of progression or death. ASH will present these progression-free survival results in full.

5. MonumenTAL-6: Tecvayli Plus Talvey Earlier in Relapsed Myeloma

Cancer type: Relapsed or refractory multiple myeloma

Abstract: 426

MonumenTAL-6 is the first phase 3 trial of a regimen that targets two myeloma proteins at once. Tecvayli (teclistamab-cqyv) is a bispecific antibody that targets BCMA, and Talvey (talquetamab-tgvs) targets GPRC5D. The trial enrolled people who had received one to four earlier treatments, including an anti-CD38 antibody and Revlimid, and compared Tecvayli plus Talvey, or Talvey plus Pomalyst (pomalidomide), with standard treatments.

In topline results announced by Johnson & Johnson in July, Tecvayli plus Talvey lowered the risk of progression or death by 89% and the risk of death by 62%. Talvey plus Pomalyst lowered the risk of progression or death by 73%. Read CURE's coverage of the topline results.

What Leukemia Studies Are on the ASH Press Program?

ASH's press program also includes leukemia studies whose results have not yet been widely reported. They include HOVON150/AMLSG29-18, a phase 3 trial of Tibsovo (ivosidenib) with intensive chemotherapy for newly diagnosed acute myeloid leukemia with an IDH1 mutation (abstract 1), and MAJIC, a phase 3 trial comparing Calquence (acalabrutinib) plus Venclexta (venetoclax) with Venclexta plus Gazyva (obinutuzumab) for untreated chronic lymphocytic leukemia (abstract 540).

What Should Patients Do With This Information?

Topline announcements come from the companies that make these drugs and are only part of the story. Full results at ASH will show how much each treatment helped, which patients benefited most and what side effects people experienced. If you have one of these cancers, ask your care team whether these findings or a related clinical trial could apply to you, and follow CURE's ASH 2026 coverage for updates.

References

  1. 68th ASH Annual Meeting and Exposition. American Society of Hematology. Accessed Nov. 16, 2026. https://www.hematology.org/Annual-Meeting
  2. Author reference guide for annual meeting abstracts. American Society of Hematology. Accessed Nov. 16, 2026. https://www.hematology.org/-/media/hematology/files/meetings/2026-author-reference-guide.pdf
  3. 2026 ASH Annual Meeting press program. American Society of Hematology. Accessed Nov. 16, 2026. https://www.hematology.org/News-and-Media/Press-Releases/2026/2026-ASH-Annual-Press-Program
  4. FDA grants priority review to zanubrutinib plus rituximab for previously untreated MCL. OncLive. Nov. 4, 2026. Accessed Nov. 16, 2026. https://www.onclive.com/view/fda-grants-priority-review-to-zanubrutinib-plus-rituximab-for-previously-untreated-mcl
  5. FDA grants priority review to zanubrutinib regimen in frontline MCL. CancerNetwork. Nov. 5, 2026. Accessed Nov. 16, 2026. https://www.cancernetwork.com/view/fda-grants-priority-review-to-zanubrutinib-regimen-in-frontline-mcl
  6. Epcoritamab plus lenalidomide improves PFS vs R-GemOx in R/R DLBCL. OncLive. June 30, 2026. Accessed Nov. 16, 2026. https://www.onclive.com/view/epcoritamab-plus-lenalidomide-improves-pfs-vs-r-gemox-in-r-r-dlbcl
  7. ADC Therapeutics announces results from LOTIS-5 phase 3 confirmatory clinical trial of ZYNLONTA in combination with rituximab in relapsed or refractory diffuse large B-cell lymphoma. ADC Therapeutics. June 3, 2026. Accessed Nov. 16, 2026. https://www.biospace.com/press-releases/adc-therapeutics-announces-results-from-lotis-5-phase-3-confirmatory-clinical-trial-of-zynlonta-in-combination-with-rituximab-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma
  8. Iberdomide combination doubles PFS vs SOC therapy in R/R multiple myeloma. CancerNetwork. Oct. 8, 2026. Accessed Nov. 16, 2026. https://www.cancernetwork.com/view/iberdomide-combination-doubles-pfs-vs-soc-therapy-in-r-r-multiple-myeloma
  9. TECVAYLI + TALVEY reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma. Johnson & Johnson. July 23, 2026. Accessed Nov. 16, 2026. https://www.jnj.com/media-center/press-releases/tecvayli-talvey-reduced-the-risk-of-disease-progression-or-death-by-89-and-the-risk-of-death-by-62-in-earlier-line-relapsed-refractory-multiple-myeloma
  10. Johnson & Johnson showcases continued hematology leadership and next-generation innovation at ASH 2026. Johnson & Johnson. Nov. 10, 2026. Accessed Nov. 16, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-continued-hematology-leadership-and-next-generation-innovation-at-ash-2026

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.


Related to this article